Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.
|Number of pages||10|
|State||Published - Nov 1 2018|
Bibliographical noteFunding Information:
PROCEED is part of the CPDPC, a cooperative agreement grant funded by the NCI (National Cancer Institute) and the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The participating sites, organizational structure of the CPDPC, and its studies are provided elsewhere in this issue of the journal29 and at http://cpdpc.mdanderson.org.
‡‡‡Division of Research, Kaiser Permanente Northern California, Oakland, CA; §§§Departments of Cell Biology and Physiology; and ||||||Human Genetics, University of Pittsburgh, UPMC, Pittsburgh, PA. Received for publication July 21, 2018; accepted August 24, 2018. Address correspondence to: Dhiraj Yadav, MD, MPH, Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, 200 Lothrop St, M2, C-wing, Pittsburgh, PA 15213 (e‐mail: email@example.com). This study was supported by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers: U01DK108288 (S.T.C., M.T.), U01DK108300 (W.G.P., A.H.), U01DK108306 (D.C.W., D.Y.), U01DK108314 (C.Y.J., S.J.P.), UO1DK108300 (C.E.F., S.J.H.), U01DK108323 (E.L.F., T.T.), U01DK108326 (W.E.F., M.O.O.), U01DK108327 (P.H., D.L.C.), and U01DK108328 (Z.F., L.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.C.W. is a consultant for AbbVie, Regeneron, and Ariel Precision Medicine, and may have equity in Ariel Precision Medicine. The other authors declare no conflict. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001170
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism